Diabetes & Metabolism Journal

Original Articles

Others
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis: Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh; Diabetes Metab J. 2024;48(2):312-320. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2022.0421

4,905 View
439 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
There is still a lack of research on which diabetic drugs are more effective in preventing stroke. Our network metaanalysis aimed to compare cerebrovascular benefits among glucose-lowering treatments.
Methods
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry for clinical trials from inception through May 25, 2021. We included both prespecified cerebrovascular outcomes and cerebrovascular events reported as severe adverse events. Subgroup analyses were conducted by stroke subtype, publication type, age of patients, baseline glycosylated hemoglobin (HbA1c), duration of type 2 diabetes mellitus, and cardiovascular risks.
Results
Of 2,861 reports and 1,779 trials screened, 79 randomized controlled trials comprising 206,387 patients fulfilled the inclusion criteria. In the pairwise meta-analysis, the use of glucagon-like peptide-1 (GLP-1) agonist was associated with a lower risk of total stroke compared with placebo (relative risk [RR], –0.17; 95% confidence interval [CI], –0.27 to –0.07). In the network meta- analysis, only the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitor was associated with a reduction of total stroke, compared with placebo (RR, 0.81; 95% CI, 0.67 to 0.98). In the subgroup analyses, the use of SGLT-2 inhibitor and GLP-1 agonist was associated with a lower risk of stroke in those with high HbA1c (≥8.0) and low-risk of cardiovascular disease, respectively.
Conclusion
SGLT-2 inhibitors and GLP-1 agonists were shown to be beneficial for stroke prevention in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Sodium-glucose cotransporter protein 2 inhibition, plasma proteins, and ischemic stroke: A mediation Mendelian randomization and colocalization study
Zhiqing Chen, Hongmei Meng, Yujin Guo, Huaiyu Sun, Wuqiong Zhang, Yu Guo, Shuai Hou
Journal of Stroke and Cerebrovascular Diseases.2025; 34(1): 108136. CrossRef
SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Jae-Han Jeon
Diabetes & Metabolism Journal.2024; 48(2): 213. CrossRef
Reply to comment on: Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyser database
Wolfgang Rathmann, Karel Kostev
Acta Diabetologica.2024; 61(8): 1081. CrossRef
Empagliflozin: Primus Inter Pares Among Sodium–Glucose Cotransporter-2 Inhibitors?
Giuseppe Biondi-Zoccai, Giacomo Frati, Mariangela Peruzzi, George W. Booz
Journal of Cardiovascular Pharmacology.2024; 84(3): 271. CrossRef
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Kathryn Haran, Chandler Johnson, Payton Smith, Zoë Venable, Allison Kranyak, Tina Bhutani, Caleb Jeon, Wilson Liao
Psoriasis: Targets and Therapy.2024; Volume 14: 143. CrossRef

Drug Regimen
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study: Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won; Diabetes Metab J. 2023;47(6):818-825. Published online November 24, 2023; DOI: https://doi.org/10.4093/dmj.2023.0171

5,855 View
449 Download
5 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).
Methods
This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk <7.5% or comprehensive lipid target (LDL-C <70 mg/dL, non-high-density lipoprotein cholesterol <100 mg/dL, and apolipoprotein B <80 mg/dL) without discontinuation, and several metabolic parameters were explored as secondary endpoints.
Results
A hundred and six participants were assigned to each group. Both groups showed significant reduction in % change of LDL-C from baseline at week 24 (–63.90±6.89 vs. –55.44±6.85, combination vs. monotherapy, p=0.0378; respectively), but the combination treatment was superior to high-intensity monotherapy in LDL-C change (%) from baseline (least square [LS] mean difference, –8.47; 95% confidence interval, –16.44 to –0.49; p=0.0378). The combination treatment showed a higher proportion of achieved comprehensive lipid targets rather than monotherapy (85.36% vs. 62.22% in monotherapy, p=0.015). The ezetimibe combination significantly improved homeostasis model assessment of β-cell function even without A1c changes (LS mean difference, 17.13; p=0.0185).
Conclusion
In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.

Citations

Citations to this article as recorded by

Clinical study on the effect of jejunoileal side-to-side anastomosis on metabolic parameters in patients with type 2 diabetes
Ji-Kui Wang, Di Zhang, Jin-Feng Wang, Wan-Lin Lu, Jing-Yuan Wang, Shi-Feng Liang, Ran Liu, Jing-Xin Jiang, Hong-Tao Li, Xuan Yang
World Journal of Diabetes.2025;[Epub] CrossRef
Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
Il Rae Park, Yong Geun Chung, Kyu Chang Won
Diabetes & Metabolism Journal.2025; 49(1): 1. CrossRef
Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
Il Rae Park, Jun Sung Moon
Diabetes & Metabolism Journal.2024; 48(3): 387. CrossRef
Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials
Aman Goyal, Muhammad Daoud Tariq, Hritvik Jain, Abhigan Babu Shrestha, Laveeza Fatima, Romana Riyaz, Hritik Raj Yadav, Darsh Safi, Abdul Qahar K. Yasinzai, Rozi Khan, Amir Humza Sohail, Mohamed Daoud, Abu Baker Sheikh
Cardiovascular Endocrinology & Metabolism.2024;[Epub] CrossRef
Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
Lingyan Liu, Yongkun Deng, Lei Li, Xingbiao Yang, Zhaoheng Yin, Yong Lai, Jaspinder Kaur
PLOS ONE.2024; 19(11): e0310696. CrossRef

Drug Regimen
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension: Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon; Diabetes Metab J. 2023;47(6):808-817. Published online September 26, 2023; DOI: https://doi.org/10.4093/dmj.2022.0387

5,116 View
427 Download
1 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination.
Methods
In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998).
Results
Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P<0.0001). The proportion of patients achieving HbA1c <7% was higher in the triple combination group at week 52 (32.14% vs. 8.51% in placebo; odds ratio, 5.62; P<0.0001). Evogliptin significantly reduced the fasting glucose levels and mean daily glucose levels with improvement in homeostatic model assessment of β-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; P=0.0138). Adverse events were similar between the groups, and no serious adverse drug reactions were reported in the evogliptin group.
Conclusion
Long-term triple combination with evogliptin added to DAPA/MET showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks and was well tolerated.

Citations

Citations to this article as recorded by

Clinical-economic assessment of the potential contribution of evogliptin to achieving the targets of the Federal project «Fight against diabetes mellitus» and reduction of population mortality
N. N. Avxentyev, A. S. Makarov, I. A. Karpova, V. V. Yavlyanskaya
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2025; (4): 55. CrossRef
Design, synthesis, and biological evaluation of quinazolinone-dihydropyrimidinone as a potential anti-diabetic agent via GLUT4 translocation stimulation
Arvind Kumar Jaiswal, Ajay Kishor Kushawaha, Pawan kumar, Alisha Ansari, Nikita Chhikara, Hemlata bhatt, Sarita Katiyar, Ishbal Ahmad, Abhijit Deb Choudhury, Rabi Sankar Bhatta, Akhilesh K. Tamrakar, Koneni V. Sashidhara
European Journal of Medicinal Chemistry.2025; 288: 117366. CrossRef
Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
Diabetes, Obesity and Metabolism.2024; 26(11): 5065. CrossRef

Review

Drug/Regimen
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs: Jang Won Son, Sungrae Kim; Diabetes Metab J. 2020;44(6):802-818. Published online December 23, 2020; DOI: https://doi.org/10.4093/dmj.2020.0258

19,835 View
1,180 Download
79 Web of Science
88 Crossref

Abstract PDF PubReader ePub

Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the treatment of obesity should be considered as an adjunct therapy. Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. Pharmacotherapy for obesity should be conducted according to a proper assessment of the clinical evidence and customized to individual patients considering the characteristics of each drug and comorbidities associated with obesity. In this review, we discuss the mechanisms of action, efficacy, and safety of these available long-term anti-obesity drugs and introduce other potential agents under investigation. Furthermore, we discuss the need for research on personalized obesity medicine.

Citations

Citations to this article as recorded by

Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
Kenneth Todd Moore, Aman Gupta, Jinshan Shen, Parag Kumar
The Journal of Clinical Pharmacology.2025; 65(2): 153. CrossRef
A review on drug repurposing applicable to obesity
Feng Chen, Kai Jing, Zhen Zhang, Xia Liu
Obesity Reviews.2025;[Epub] CrossRef
Unraveling the Anti-Obesity Potential of Luteolin: Mechanistic Insights
Akhil Sharma, Gagandeep Kaur, Amandeep Kaur, Sushma Devi
Current Nutrition & Food Science.2025; 21(3): 295. CrossRef
Lipid nanosystems for fatty liver therapy and targeted medication delivery: a comprehensive review
Chuipeng Liang, Xing Liu, Zihao Sun, Lin Wen, Jijiao Wu, Sanjun Shi, Xiaolian Liu, Nini Luo, Xiaofang Li
International Journal of Pharmaceutics.2025; 669: 125048. CrossRef
Shedding light on weight loss: A narrative review of medications for treating obesity
Haritha Darapaneni, Samridhi Lakhanpal, Hiren Chhayani, Kinna Parikh, Meet Patel, Vasu Gupta, Fnu Anamika, Ripudaman Munjal, Rohit Jain
Romanian Journal of Internal Medicine.2024; 62(1): 3. CrossRef
Projected health and economic effects of the increase in childhood obesity during the COVID-19 pandemic in England: The potential cost of inaction
Iván Ochoa-Moreno, Ravita Taheem, Kathryn Woods-Townsend, Debbie Chase, Keith M. Godfrey, Neena Modi, Mark Hanson, Rebecca F. Baggaley
PLOS ONE.2024; 19(1): e0296013. CrossRef
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, Mohammad Zulqurnain Haider, Mohammed Imad Malki, Abdel-Naser Elzouki
Frontiers in Medicine.2024;[Epub] CrossRef
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Manmeet Kaur, Saurav Misra
European Journal of Clinical Pharmacology.2024; 80(5): 669. CrossRef
Gut microbiota and therapy for obesity and type 2 diabetes
Luyao Zhang, Pai Wang, Juan Huang, Yanpeng Xing, F. Susan Wong, Jian Suo, Li Wen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Adipocyte-targeted delivery of rosiglitazone with localized photothermal therapy for the treatment of diet-induced obesity in mice
Yunxiao Zhang, Maoqi Luo, Yaxin Jia, Tingting Gao, Li Deng, Tao Gong, Zhirong Zhang, Xi Cao, Yao Fu
Acta Biomaterialia.2024; 181: 317. CrossRef
Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis
Leonardo Zumerkorn Pipek, Walter Augusto Fabio Moraes, Rodrigo Massato Nobetani, Vitor Santos Cortez, Alberto Santos Condi, João Victor Taba, Rafaela Farias Vidigal Nascimento, Milena Oliveira Suzuki, Fernanda Sayuri do Nascimento, Vitoria Carneiro de Mat
Scientific Reports.2024;[Epub] CrossRef
Free radical scavenging, α-amylase, α-glucosidase, and lipase inhibitory activities of metabolites from strawberry kombucha: Molecular docking and in vitro studies
Adriyan Pramono, William Ben Gunawan, Fahrul Nurkolis, Darmawan Alisaputra, Gilbert Ansell Limen, Muhammad Subhan Alfaqih, Martha Ardiaria
Pharmacia.2024; 71: 1. CrossRef
“Dare to feel full”—A group treatment method for sustainable weight reduction in overweight and obese adults: A randomized controlled trial with 5-years follow-up
Sara Holmberg, Lena Lendahls, Kjell-Åke Alle, Aleksandra Klisic
PLOS ONE.2024; 19(5): e0303021. CrossRef
ANÁLISE DA PERDA DE PESO EM PACIENTES SUBMETIDOS A CIRURGIA BARIÁTRICA: REVISÃO SISTEMÁTICA DE LITERATURA
Lucas Bottesini dos Santos, Eduardo Barbosa Lopes, Cristianne Confessor Castilho Lopes, Suellen Balbinoti Fuzinatto, Maykon Ribeiro, Guilherme Lange, Viviane Dorgievicz, Éder Ricardo Haag, Yan Fincatto, Vanessa Macrhy
Revista Contemporânea.2024; 4(5): e4260. CrossRef
Kaempferia parviflora extract and its component polymethoxyflavones suppress adipogenic differentiation of human bone marrow-derived mesenchymal stem cells via the AMPK pathway
Masakazu Ishii, Haruka Miyata, Nao Ikeda, Tomoaki Sakurai, Yurika Oura, Masahiro Nishimura
Molecular Biology Reports.2024;[Epub] CrossRef
What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review
Kate Maslin, Rabab Alkutbe, Jeremy Gilbert, Jonathan Pinkney, Jill Shawe
Clinical Obesity.2024;[Epub] CrossRef
Effect of Lythrum salicaria Extract on Body Fat Reduction: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
Hye-Jin Park, In Heo, Yea-Jin Park, Hyo-Jin An, Su Shin, Yun-Yeop Cha
Journal of Korean Medicine for Obesity Research.2024; 24(1): 87. CrossRef
Obesity and Weight Loss Strategies for Patients With Heart Failure
Amanda R. Vest, Philip R. Schauer, Jo E. Rodgers, Emily Sanderson, Courtney L. LaChute, Jessica Seltz, Carl J. Lavie, Stacy A. Mandras, W.H. Wilson Tang, Adrian daSilva-deAbreu
JACC: Heart Failure.2024; 12(9): 1509. CrossRef
The Effects of Propolis Consumption on Body Composition and Blood Pressure: A Systematic Review and Dose-Response Meta-Analysis
Mahdi Vajdi, Atefeh Bonyadian, Fatemeh Pourteymour Fard Tabrizi, Reza Hassanizadeh, Nooshin Noshadi, Beitullah Alipour, Mahdieh Abbasalizad-Farhangi, Melika Darzi, Sahar Golpour-Hamedani, Gholamreza Askari
Current Therapeutic Research.2024; 101: 100754. CrossRef
Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds
Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri
Heliyon.2024; 10(16): e35498. CrossRef
Association between glucagon‐like peptide‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, Hanseul Cho, Jaeyu Park, Hyesu Jo, Yejun Son, Soeun Kim, Jiseung Kang, Lee Smith, Masoud Rahmati, Guillaume Fond, Laurent Boyer, Damiano Pizzol, Hayeon Lee, Sang Youl Rhee, Jiyoung Hwang, Hyunji Sang, Dong Keon
Diabetes, Obesity and Metabolism.2024; 26(11): 5183. CrossRef
Adipocyte-Targeted Nanocomplex with Synergistic Photothermal and Pharmacological Effects for Combating Obesity and Related Metabolic Syndromes
Yuanyuan Zhang, Xiaojiao Zeng, Fan Wu, Xiaopeng Yang, Tingting Che, Yin Zheng, Jie Li, Yufei Zhang, Xinge Zhang, Zhongming Wu
Nanomaterials.2024; 14(16): 1363. CrossRef
Advancements in Understanding and Preventing Obesity-Related Colon Cancer
Christine Shieh, Henry J. Thompson, Eric McLaughlin, Chien-Wei Chiang, Hisham Hussan
The Cancer Journal.2024; 30(5): 357. CrossRef
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Federico Losada-Díaz, Santiago Lizarazo-Bocanegra, Juan J. Perdomo-Lugo, Sebastián A. Gutiérrez-Romero, Isabella Correa-Osio, Carlos O. Mendivil
Diabetes Therapy.2024; 15(11): 2279. CrossRef
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H. Naylor, P. Gerry Fegan, Bu B. Yeap, Daniel J. Green
Diabetes Care.2024; 47(10): 1718. CrossRef
Lactobacillus acidophilus CICC 6075 attenuates high-fat diet-induced obesity by improving gut microbiota composition and histidine biosynthesis
Shenyang ZHANG, Shuai YANG, Yun ZHUANG, Dan YANG, Xiqun GU, Yi WANG, Zhenzhen WANG, Renjin CHEN, Fuling YAN
Bioscience of Microbiota, Food and Health.2024; 43(4): 367. CrossRef
Medicinal Plants and Natural Products to Treat Obesity through Inhibiting Pancreatic Lipase: A Review (2020-2022)
Khaoula Jamai, Nour Elhouda Daoudi, Amal Elrherabi, Mohamed Bnouham
Letters in Drug Design & Discovery.2024; 21(11): 1936. CrossRef
Withanolides-enriched leaf extract of Withania somnifera exert anti-obesity effects by inducing brown adipocyte-like phenotype via tuning MAP-kinase signaling axis
Acharya Balkrishna, Priya Kumari, Pratibha Singh, Nishit Pathak, Sudeep Verma, Rishabh Dev, Anurag Varshney
International Journal of Biological Macromolecules.2024; 282: 136883. CrossRef
Morus alba: natural and valuable effects in weight loss management
Foteini Ntalouka, Athina Tsirivakou
Frontiers in Clinical Diabetes and Healthcare.2024;[Epub] CrossRef
Effects of gastric bypass bariatric surgery on gut microbiota in patients with morbid obesity
Urja Amin, Dora Huang, Arun Dhir, Anya E Shindler, Ashley E Franks, Colleen J Thomas
Gut Microbes.2024;[Epub] CrossRef
Como tratar a obesidade associada à diabetes tipo 2?
Carina Proença, Ana T. Rufino, Marisa Freitas, Eduarda Fernandes
Revista de Ciência Elementar.2024;[Epub] CrossRef
Exploration of the Mechanism of Guaijaverin in Inhibiting Pancreatic Lipase Based on Multispectral Method, Molecular Docking, and Oral Lipid Tolerance Test in Rats
Xinyu Gao, Kaijie Jia, Hong Li, Shujun Liu, Yang Wang, Jinlong Tian, Xin Zhao, Pan Zhao
Luminescence.2024;[Epub] CrossRef
Review on obesity management: diet, exercise and pharmacotherapy
Katya Peri, Mark Eisenberg
BMJ Public Health.2024; 2(2): e000246. CrossRef
Efficacy of endoscopic resuturing versus pharmacotherapy to treat weight recidivism after endoscopic sleeve gastroplasty
Kaveh Hajifathalian, Okeefe Simmons, Mohamed Abu-Hammour, Kamal Hassan, Reem Z. Sharaiha
Gastrointestinal Endoscopy.2023; 98(6): 944. CrossRef
Gardenia fruit and Eucommia leaves combination improves hyperlipidemia and hyperglycemia via pancreatic lipase and AMPK-PPARα and Keap-1-Nrf2-HO-1 regulation
Xiaotong Su, Shun Hao, Wenna Li, Xu Li, Zhentao Mo, Yiqi Li, Lu Xiao, Wenjun Wang, Feng Wang
Journal of Functional Foods.2023; 100: 105394. CrossRef
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo
Journal of Experimental & Clinical Cancer Research.2023;[Epub] CrossRef
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Gideon G. Kang, Natalie L. Trevaskis, Andrew J. Murphy, Mark A. Febbraio
iScience.2023; 26(1): 105905. CrossRef
The gut microbiota in obesity and weight management: microbes as friends or foe?
Matthias Van Hul, Patrice D. Cani
Nature Reviews Endocrinology.2023; 19(5): 258. CrossRef
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum‐Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M. Hennige
Diabetes, Obesity and Metabolism.2023; 25(4): 1011. CrossRef
From Metabolic Syndrome to Type 2 Diabetes in Youth
Dario Iafusco, Roberto Franceschi, Alice Maguolo, Salvatore Guercio Nuzio, Antonino Crinò, Maurizio Delvecchio, Lorenzo Iughetti, Claudio Maffeis, Valeria Calcaterra, Melania Manco
Children.2023; 10(3): 516. CrossRef
Excess body weight: Novel insights into its roles in obesity comorbidities
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, Jun Yu
Seminars in Cancer Biology.2023; 92: 16. CrossRef
Striatal dopamine D2-like receptors availability in obesity and its modulation by bariatric surgery: a systematic review and meta-analysis
Gabriela Ribeiro, Ana Maia, Gonçalo Cotovio, Francisco P. M. Oliveira, Durval C. Costa, Albino J. Oliveira-Maia
Scientific Reports.2023;[Epub] CrossRef
Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
Ainhoa Gómez Lumbreras, Malinda S. Tan, Lorenzo Villa-Zapata, Sabrina Ilham, Jacob C. Earl, Daniel C. Malone
Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(6): 1268. CrossRef
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer
Simon P. de Leeuw, Melinda A. Pruis, Barend J. Sikkema, Mostafa Mohseni, G. D. Marijn Veerman, Marthe S. Paats, Daphne W. Dumoulin, Egbert F. Smit, Annemie M.W. J. Schols, Ron H.J. Mathijssen, Elisabeth F.C. van Rossum, Anne-Marie C. Dingemans
Journal of Thoracic Oncology.2023; 18(8): 1017. CrossRef
Role of flavonoids in controlling obesity: molecular targets and mechanisms
Anns Mahboob, Samson Mathews Samuel, Arif Mohamed, Mohmmad Younus Wani, Sofiane Ghorbel, Nabil Miled, Dietrich Büsselberg, Ali Chaari
Frontiers in Nutrition.2023;[Epub] CrossRef
The N-degron pathway mediates lipophagy: The chemical modulation of lipophagy in obesity and NAFLD
Eui Jung Jung, Ki Woon Sung, Tae Hyun Bae, Hee-Yeon Kim, Ha Rim Choi, Sung Hyun Kim, Chan Hoon Jung, Su Ran Mun, Yeon Sung Son, Shin Kim, Young Ho Suh, Anna Kashina, Joo-Won Park, Yong Tae Kwon
Metabolism.2023; 146: 155644. CrossRef
Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation
Austin Clark, Brendan Tate, Bretton Urban, Ryan Schroeder, Sonja Gennuso, Shahab Ahmadzadeh, David McGregor, Brook Girma, Sahar Shekoohi, Alan D. Kaye
Health Psychology Research.2023;[Epub] CrossRef
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
Benudhara Pati, Satyabrata Sendh, Bijayashree Sahu, Sunil Pani, Nivedita Jena, Naresh Chandra Bal
RSC Medicinal Chemistry.2023; 14(8): 1429. CrossRef
Management of abdominal wall hernias in patients with severe obesity
Omar M. Ghanem, Sean Orenstein, S. Julie-Ann Lloyd, Amin Andalib, Alice Race, Holly Ann Burt, Farah Husain, Matthew Goldblatt, Matthew Kroh
Surgical Endoscopy.2023; 37(9): 6619. CrossRef
Obesity-related hypertension and chronic kidney disease: from evaluation to management
Mi-Hyang Jung, Sang-Hyun Ihm
Kidney Research and Clinical Practice.2023; 42(4): 431. CrossRef
Antiepileptics pharmacotherapy or antidiabetics may hold potential in ‎treatment of ‎‎epileptic ‎patients with diabetes mellitus: A narrative review
Marwan AL-NİMER, Saeed AL-ZUHAİRY
Hacettepe University Journal of the Faculty of Pharmacy.2023;[Epub] CrossRef
Medicamentos antidiabéticos utilizados com a finalidade de perda de peso
Sâmia Moreira de ANDRADE, Maria Victória Macedo de ANDRADE, Pedro Henrique Almeida de FARIA, Luís Marcelo Vieira ROSA, Plínio Robson Cavalcante COSTA, Luiz Gustavo Freitas PIRES
Diversitas Journal.2023;[Epub] CrossRef
Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon
Christian L. Roth, Anna Zenno
Frontiers in Endocrinology.2023;[Epub] CrossRef
Obesity: What’s Old, What’s New and How We Manage It: An Integrated Approach in Pharmacy Practice
Ângelo Jesus
FarmaJournal.2023; 8(2): 45. CrossRef
Integrating Pharmacotherapy and Psychotherapy for Weight Loss
Marla Sanzone, Morgan Sammons
Journal of Health Service Psychology.2023; 49(4): 177. CrossRef
Effect of Lingguizhugan decoction in activating fat mobilization in obesity
Yubin YANG, Yunlong WANG, Zhengbang SUN, Ting DU, Ying YANG, Jiaojiao CHEN, Meiling WANG, Hairong LI, Jian QIN
Journal of Holistic Integrative Pharmacy.2022; 3(1): 68. CrossRef
Computational approaches to predicting treatment response to obesity using neuroimaging
Leonard Kozarzewski, Lukas Maurer, Anja Mähler, Joachim Spranger, Martin Weygandt
Reviews in Endocrine and Metabolic Disorders.2022; 23(4): 773. CrossRef
Delivery of miRNAs to the adipose organ for metabolic health
Karin Kornmueller, Ez-Zoubir Amri, Marcel Scheideler, Ruth Prassl
Advanced Drug Delivery Reviews.2022; 181: 114110. CrossRef
Purple sweet potato leaf extracts suppress adipogenic differentiation of human bone marrow–derived mesenchymal stem cells
Masakazu Ishii, Nao Ikeda, Haruka Miyata, Manami Takahashi, Masahiro Nishimura
Journal of Food Biochemistry.2022;[Epub] CrossRef
The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models
Jianbo Wu, Kenchi Miyasaka, Wakana Yamada, Shogo Takeda, Norihito Shimizu, Hiroshi Shimoda
Molecules.2022; 27(3): 607. CrossRef
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research
María Florencia González Bagnes, Claudio González, Valeria Hirschler, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy.2022; 23(8): 869. CrossRef
Russelioside B: a Pregnane Glycoside with Pharmacological Potential
Essam Abdel-Sattar, Dalia E. Ali
Revista Brasileira de Farmacognosia.2022; 32(2): 188. CrossRef
Pharmacotherapy in Childhood Obesity
Peter Kühnen, Heike Biebermann, Susanna Wiegand
Hormone Research in Paediatrics.2022; 95(2): 177. CrossRef
Effects of Vinegar/Acetic Acid Intake on Appetite Measures and Energy Consumption: Systematic Review
Faten O. Hasan, Kristen P. Hamilton, Siddhartha S. Angadi, Sibylle Kranz
Translational Journal of the American College of Sports Medicine.2022;[Epub] CrossRef
Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management
Fajuan Rui, Hongli Yang, Xinyu Hu, Qi Xue, Yayun Xu, Junping Shi, Jie Li
Infectious Microbes and Diseases.2022; 4(2): 49. CrossRef
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health
Aadi Sharma, Somaya Albhaisi, Arun J. Sanyal
Clinical Liver Disease.2022; 20(2): 48. CrossRef
A narrative review of anti-obesity medications for obese patients with osteoarthritis
Win Min Oo, Ali Mobasheri, David J Hunter
Expert Opinion on Pharmacotherapy.2022; 23(12): 1381. CrossRef
Sulfated Glucan from the Green Seaweed Caulerpa sertularioides Inhibits Adipogenesis through Suppression of Adipogenic and Lipogenic Key Factors
Gildacio Chaves Filho, Lucas Batista, Silvia de Medeiros, Hugo Rocha, Susana Moreira
Marine Drugs.2022; 20(8): 470. CrossRef
Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
Nasser M Alorfi, Alanood S Algarni
Clinical Pharmacology: Advances and Applications.2022; Volume 14: 61. CrossRef
The Role of Gut Microbiota Modulation Strategies in Obesity: The Applications and Mechanisms
Lingyue Shan, Akanksha Tyagi, Umair Shabbir, Xiuqin Chen, Selvakumar Vijayalakshmi, Pianpian Yan, Deog-Hwan Oh
Fermentation.2022; 8(8): 376. CrossRef
Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota
Jin Jin, Jiani Wang, Ruyue Cheng, Yan Ren, Zhonghua Miao, Yating Luo, Qingqing Zhou, Yigui Xue, Xi Shen, Fang He, Haoming Tian
Frontiers in Microbiology.2022;[Epub] CrossRef
N-linoleyltyrosine ameliorates high-fat diet-induced obesity in C57BL/6 mice via cannabinoid receptor regulation
Zheng-yu Yang, Yi-ying Wu, Yi Zhou, Yun-qi Yang, Jia-hui Zhang, Tao He, Sha Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults
Megan O. Bensignor, Aaron S. Kelly, Silva Arslanian
Frontiers in Endocrinology.2022;[Epub] CrossRef
Blockade of CXXC5-dishevelled interaction inhibits adipogenic differentiation, obesity, and insulin resistance in mice
Seol Hwa Seo, Dasung Lee, Soung-Hoon Lee, Kang-Yell Choi
Scientific Reports.2022;[Epub] CrossRef
Effect of the Melanocortin 4-Receptor Ile269Asn Mutation on Weight Loss Response to Dietary, Phentermine and Bariatric Surgery Interventions
Itzel G. Salazar-Valencia, Hugo Villamil-Ramírez, Francisco Barajas-Olmos, Martha Guevara-Cruz, Luis R. Macias-Kauffer, Humberto García-Ortiz, Omar Hernández-Vergara, David Alberto Díaz de Sandy-Galán, Paola León-Mimila, Federico Centeno-Cruz, Luis E. Gon
Genes.2022; 13(12): 2267. CrossRef
A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
Clara García-Carro, Ander Vergara, Sheila Bermejo, María A. Azancot, Joana Sellarés, Maria José Soler
Frontiers in Medicine.2021;[Epub] CrossRef
Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery
Marvin Wei Jie Chua, Boon Cheok Lai
Obesity Surgery.2021; 31(8): 3874. CrossRef
BMI Course Over 10 Years After Bariatric Surgery and Biopsychosocial Complexity Assessed with the INTERMED: a Retrospective Study
Yann Corminboeuf, Beate Wild, Catherine Zdrojewski, Dieter Schellberg, Lucie Favre, Michel Suter, Friedrich Stiefel
Obesity Surgery.2021; 31(9): 3996. CrossRef
The Role of Positron Emission Tomography in Bariatric Surgery Research: a Review
Jason Bini, Mathieu Norcross, Maija Cheung, Andrew Duffy
Obesity Surgery.2021; 31(10): 4592. CrossRef
Anti-Obesity Effect of Hot Water Extract of Barley Sprout through the Inhibition of Adipocyte Differentiation and Growth
Myeong-Jin Kim, Hye-Won Kawk, Sang-Hyeon Kim, Hyo-Jae Lee, Ji-Won Seo, Jong-Tae Kim, Seung-Hee Jang, Min-Jeong Kim, Young-Min Kim
Metabolites.2021; 11(9): 610. CrossRef
Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes
Wona Jee, Seung-Hyeon Lee, Hyun Min Ko, Ji Hoon Jung, Won-Seok Chung, Hyeung-Jin Jang
International Journal of Molecular Sciences.2021; 22(19): 10405. CrossRef
The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice
Nabil Rabhi, Kathleen Desevin, Briana Noel Cortez, Ryan Hekman, Jean Z. Lin, Andrew Emili, Stephen R. Farmer
Scientific Reports.2021;[Epub] CrossRef
Chlorogenic Acids Inhibit Adipogenesis: Implications of Wnt/β-Catenin Signaling Pathway
Mengting Liu, Jian Qin, Jing Cong, Yubin Yang, Muhittin Yurekli
International Journal of Endocrinology.2021; 2021: 1. CrossRef
Médicaments anti-obésité : leçons des échecs pour l’avenir
André J. Scheen
Médecine des Maladies Métaboliques.2021; 15(8): 734. CrossRef
Obesity and Eating Disorders in Children and Adolescents: The Bidirectional Link
Stella Stabouli, Serap Erdine, Lagle Suurorg, Augustina Jankauskienė, Empar Lurbe
Nutrients.2021; 13(12): 4321. CrossRef
MEK6 Overexpression Exacerbates Fat Accumulation and Inflammatory Cytokines in High-Fat Diet-Induced Obesity
Suyeon Lee, Myoungsook Lee
International Journal of Molecular Sciences.2021; 22(24): 13559. CrossRef
Skin and obesity in childhood: an update
Valeria Hirschler
AIMS Medical Science.2021; 8(4): 311. CrossRef
An Avocado Extract Enriched in Mannoheptulose Prevents the Negative Effects of a High-Fat Diet in Mice
Paul J. Pistell, Tadanobu Utsuki, Joseph Francis, Philip J. Ebenezer, Jennifer Terrebonne, George S. Roth, Donald K. Ingram
Nutrients.2021; 14(1): 155. CrossRef

Brief Report

Drug/Regimen
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus: Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon; Diabetes Metab J. 2021;45(6):954-959. Published online November 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0173

56,906 View
411 Download
4 Web of Science
3 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.

Citations

Citations to this article as recorded by

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2024; 48(5): 915. CrossRef
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
Diabetes & Metabolism Journal.2021; 45(4): 461. CrossRef

Review

Metabolic Risk/Epidemiology
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming: Soung Won Jeong; Diabetes Metab J. 2020;44(5):640-657. Published online October 21, 2020; DOI: https://doi.org/10.4093/dmj.2020.0115

13,888 View
582 Download
18 Web of Science
18 Crossref

Abstract PDF PubReader ePub

The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.

Citations

Citations to this article as recorded by

Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan
Biomolecules.2025; 15(1): 140. CrossRef
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin
Current Drug Therapy.2024; 19(1): 20. CrossRef
Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review
Pervej Alom Barbhuiya, Saikat Sen, Manash Pratim Pathak
Phytochemistry Reviews.2024; 23(4): 969. CrossRef
Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection
Shibing Tao, Shanlan Guo, Nanwei Tong
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2024; 44(8): 642. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
Willy B Theel, Bianca M Boxma-de Klerk, Femme Dirksmeier-Harinck, Elisabeth FC van Rossum, Danny A Kanhai, Jan A Apers, Bas M van Dalen, Robert J De Knegt, Bojou Neecke, Ellen M van der Zwan, Diederick E Grobbee, Thomas Hankemeier, Janneke Wiebolt, Manuel
BMJ Open.2023; 13(7): e070431. CrossRef
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Youngmin A. Lee, Scott L. Friedman
Journal of Internal Medicine.2022; 291(1): 11. CrossRef
Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(4): 752. CrossRef
Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2022; 30(6): 1279. CrossRef
Thyroid diseases and new approaches for their treatment
E. A. Fokina, A. O. Shpakov
The Siberian Journal of Clinical and Experimental Medicine.2022; 37(3): 90. CrossRef
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
Giang Nguyen, So Young Park, Dinh Vinh Do, Dae-Hee Choi, Eun-Hee Cho
Endocrinology and Metabolism.2022; 37(6): 918. CrossRef
Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH
Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Yeonhwa Song, Namjeong Kim, Hyung Chul Ryu, Jee Woong Lim, Hyo Jin Kang, Jason Kim, Haeng Ran Seo
Cell Death & Disease.2022;[Epub] CrossRef
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan
International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh
International Journal of Molecular Sciences.2021; 22(9): 4495. CrossRef
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
Scientific Reports.2021;[Epub] CrossRef
Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis
João Remí de Freitas Júnior, Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Vitor Massaro Takamatsu Sagae, Gabriel Mayo Vieira de Souza, Guilherme Henrique Peixoto de Oliveira, Sergio A Sánchez-Luna, Thiago Ferreira de Souza, Eduardo Turiani Hourne
World Journal of Hepatology.2021; 13(7): 815. CrossRef
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Branka Filipovic, Snezana Lukic, Dragana Mijac, Marija Marjanovic-Haljilji, Marko Vojnovic, Jelena Bogdanovic, Tijana Glisic, Natasa Filipovic, Jamal Al Kiswani, Aleksandra Djokovic, Suncica Kapor, Slobodan Kapor, Zoran Bukumiric, Ana Starcevic
International Journal of Molecular Sciences.2021; 22(24): 13219. CrossRef

Original Articles

Drug/Regimen
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study: Jun Sung Moon, Sunghwan Suh, Sang Soo Kim, Heung Yong Jin, Jeong Mi Kim, Min Hee Jang, Kyung Ae Lee, Ju Hyung Lee, Seung Min Chung, Young Sang Lyu, Jin Hwa Kim, Sang Yong Kim, Jung Eun Jang, Tae Nyun Kim, Sung Woo Kim, Eonju Jeon, Nan Hee Cho, Mi-Kyung Kim, Hye Soon Kim, Il Seong Nam-Goong, Eun Sook Kim, Jin Ook Chung, Dong-Hyeok Cho, Chang Won Lee, Young Il Kim, Dong Jin Chung, Kyu Chang Won, In Joo Kim, Tae Sun Park, Duk Kyu Kim, Hosang Shon; Diabetes Metab J. 2021;45(5):675-683. Published online August 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0107

37,449 View
402 Download
12 Web of Science
8 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background

Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM).

Methods

From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated.

Results

In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9±14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, −1.1%±1.2%; P<0.001). The number of patients with HbA1c <7% increased significantly from 5 to 68 (P<0.005). In addition, lipid profiles and liver enzyme levels were also improved whereas no changes in body weight. There was no significant safety issue in patients treated with quadruple OHA therapy.

Conclusion

This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy.

Citations

Citations to this article as recorded by

Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Fatemeh Moosaie, Shiva Abedinzadeh, Soghra Rabizadeh, Kimia Daneshvar, Mohammadamin Noorafrooz, Fatemeh Alsadat Mojtahedi, Niloofar Deravi, Seyede Marzie Fatemi Abhari, Akam Ramezani, Alipasha Meysamie, Marzieh Hajibabaei, Sahar Karimpour Reyhan, Mahsa Ab
Scientific Reports.2025;[Epub] CrossRef
Estimating Type 2 Diabetes Prevalence: A Model of Drug Consumption Data
Rita Oliveira, Matilde Monteiro-Soares, José Pedro Guerreiro, Rúben Pereira, António Teixeira-Rodrigues
Pharmacy.2024; 12(1): 18. CrossRef
Disease burden and symptom management in type 2 diabetic patients: A phenomenological study
Sevgi Demir Çam, Sevda Uzun
Public Health Nursing.2024; 41(6): 1291. CrossRef
Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study
Nadia Gul, Inayat Ur Rehman, Yasar shah, Arbab Muhammad Ali, Zahid Ali, Omer Shehzad, Khang Wen Goh, Long Chiau Ming, Amal K. Suleiman, Nimesh Lageju
PLOS ONE.2024; 19(11): e0311435. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study
Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(6): 1105. CrossRef
A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef

Drug/Regimen
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study: Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim; Diabetes Metab J. 2020;44(1):67-77. Published online July 11, 2019; DOI: https://doi.org/10.4093/dmj.2018.0274

9,412 View
196 Download
9 Web of Science
11 Crossref

Abstract PDF PubReader

Background

There is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. This study assessed the efficacy and safety of pioglitazone or glimepiride when added to metformin plus alogliptin treatment for T2DM.

Methods

This multicenter, randomized, active-controlled trial (ClinicalTrials.gov: NCT02426294) recruited 135 Korean patients with T2DM that was inadequately controlled using metformin plus alogliptin. The patients were then randomized to also receive pioglitazone (15 mg/day) or glimepiride (2 mg/day) for a 26-week period, with dose titration was permitted based on the investigator's judgement.

Results

Glycosylated hemoglobin levels exhibited similar significant decreases in both groups during the treatment period (pioglitazone: −0.81%, P<0.001; glimepiride: −1.05%, P<0.001). However, the pioglitazone-treated group exhibited significantly higher high density lipoprotein cholesterol levels (P<0.001) and significantly lower homeostatic model assessment of insulin resistance values (P<0.001). Relative to pioglitazone, adding glimepiride to metformin plus alogliptin markedly increased the risk of hypoglycemia (pioglitazone: 1/69 cases [1.45%], glimepiride: 14/66 cases [21.21%]; P<0.001).

Conclusion

Among patients with T2DM inadequately controlled using metformin plus alogliptin, the addition of pioglitazone provided comparable glycemic control and various benefits (improvements in lipid profiles, insulin resistance, and hypoglycemia risk) relative to the addition of glimepiride.

Citations

Citations to this article as recorded by

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2024; 48(5): 915. CrossRef
Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study
Yun Kyung Cho, Kyung-Soo Kim, Byung-Wan Lee, Jun Hwa Hong, Jae Myung Yu, Soo Lim, Ye An Kim, Chang Beom Lee, Sang Soo Kim, Soo Heon Kwak, Woo Je Lee
Clinical Therapeutics.2024; 46(9): 662. CrossRef
Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Ji Hye Heo, Kyung Ah Han, Jun Hwa Hong, Hyun-Ae Seo, Eun-Gyoung Hong, Jae Myung Yu, Hye Seung Jung, Bong-Soo Cha
Diabetes & Metabolism Journal.2024; 48(5): 937. CrossRef
A Green Approach: Optimization of the UPLC Method Using DoE Software for Concurrent Quantification of Pioglitazone and Dapagliflozin in a SNEDDS Formulation for the Treatment of Diabetes
Ehab M. Elzayat, Abdelrahman Y. Sherif, Mohamed W. Attwa, Mohammad A. Altamimi
ACS Omega.2024; 9(45): 45011. CrossRef
Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus
Yu.V. Strunina, N.A. Petunina
Medical Technologies. Assessment and Choice.2023; (3): 70. CrossRef
Pioglitazone-Enhanced Brown Fat Whitening Contributes to Weight Gain in Diet-Induced Obese Mice
Piaojian Yu, Wei Wang, Wanrong Guo, Lidan Cheng, Zhiping Wan, Yanglei Cheng, Yunfeng Shen, Fen Xu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(11): 595. CrossRef
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
Joaquim Barreto, Beatriz Luchiari, Vaneza L. W. Wolf, Isabella Bonilha, Ticiane G. Bovi, Barbara S. Assato, Ikaro Breder, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Thiago Quinaglia, Otavio R. Coelho-Filho, Luiz Sergio F. Carvalho, Wilson Nadruz, Andrei
Diagnostics.2022; 12(4): 814. CrossRef
Effects of Glimepiride Combined with Recombinant Human Insulin Injection on Serum IGF-1, VEGF and TRACP-5b Oxidative Stress Levels in Patients with Type 2 Diabetes Mellitus
Xue Chen, Sheng Kang, Zeqing Bao, Ciara Hughes
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
Development and validation of a sensitive LC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats
Kusuma Kumari G., Praveen Thaggikuppe Krishnamurthy, Ravi Kiran Ammu V. V. V., Kurawattimath Vishwanath, S. T. Narenderan, B. Babu, Nagappan Krishnaveni
RSC Advances.2021; 11(19): 11437. CrossRef
Compliance with Cardiovascular Prevention Guidelines in Individuals with Type 2 Diabetes in a Middle-Income Region: Cross-Sectional Analysis
Joaquim Barreto, Beatriz Luchiari, Vaneza Lira W. Wolf, Isabella Bonilha, Ticiane G. Bovi, Barbara S. Assato, Ikaro Breder, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Thiago Quinaglia, Otavio R. Coelho-Filho, Luiz Sérgio Fernandes de Carvalho, Wilson Na
SSRN Electronic Journal .2021;[Epub] CrossRef

Clinical Diabetes & Therapeutics
Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study: Hae Kyung Yang, Seung-Hwan Lee, Juyoung Shin, Yoon-Hee Choi, Yu-Bae Ahn, Byung-Wan Lee, Eun Jung Rhee, Kyung Wan Min, Kun-Ho Yoon; Diabetes Metab J. 2019;43(3):287-301. Published online December 20, 2018; DOI: https://doi.org/10.4093/dmj.2018.0054

7,698 View
127 Download
15 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader

Background

We evaluated the efficacy and safety of acarbose add-on therapy in Korean patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with metformin and sitagliptin.

Methods

A total of 165 subjects were randomized to metformin and sitagliptin (Met+Sita, n=65), metformin, sitagliptin, and acarbose (Met+Sita+Acarb, n=66) and sitagliptin and acarbose (Sita+Acarb, exploratory assessment, n=34) therapy in five institutions in Korea. After 16 weeks of acarbose add-on or metformin-switch therapy, a triple combination therapy was maintained from week 16 to 24.

Results

The add-on of acarbose (Met+Sita+Acarb group) demonstrated a 0.44%±0.08% (P<0.001 vs. baseline) decrease in glycosylated hemoglobin (HbA1c) at week 16, while changes in HbA1c were insignificant in the Met+Sita group (−0.09%±0.10%, P=0.113). After 8 weeks of triple combination therapy, HbA1c levels were comparable between Met+Sita and Met+Sita+Acarb group (7.66%±0.13% vs. 7.47%±0.12%, P=0.321). Acarbose add-on therapy demonstrated suppressed glucagon secretion (area under the curve of glucagon, 4,726.17±415.80 ng·min/L vs. 3,314.38±191.63 ng·min/L, P=0.004) in the absence of excess insulin secretion during the meal tolerance tests at week 16 versus baseline. The incidence of adverse or serious adverse events was similar between two groups.

Conclusion

In conclusion, a 16-week acarbose add-on therapy to metformin and sitagliptin, effectively lowered HbA1c without significant adverse events. Acarbose might be a good choice as a third-line therapy in addition to metformin and sitagliptin in Korean subjects with T2DM who have predominant postprandial hyperglycemia and a high carbohydrate intake.

Citations

Citations to this article as recorded by

The effect of acarbose on inflammatory cytokines and adipokines in adults: a systematic review and meta-analysis of randomized clinical trials
Ali Mohammadian, Sahand Tehrani Fateh, Mahlagha Nikbaf-Shandiz, Fatemeh Gholami, Niloufar Rasaei, Hossein Bahari, Samira Rastgoo, Reza Bagheri, Farideh Shiraseb, Omid Asbaghi
Inflammopharmacology.2024; 32(1): 355. CrossRef
An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides
Sachithanantham Annapoorani Sivaraman, Varatharajan Sabareesh
Current Protein & Peptide Science.2024; 25(4): 267. CrossRef
The effect of acarbose treatment on anthropometric indices in adults: A systematic review and meta-analysis of randomized clinical trials
Elnaz Golalipour, Dorsa Hosseininasab, Mahlagha Nikbaf-Shandiz, Niloufar Rasaei, Hossein Bahari, Mahya Mehri Hajmir, Samira Rastgoo, Farideh Shiraseb, Omid Asbaghi
Clinical Nutrition Open Science.2024; 56: 166. CrossRef
Deciphering Molecular Aspects of Potential α-Glucosidase Inhibitors within Aspergillus terreus: A Computational Odyssey of Molecular Docking-Coupled Dynamics Simulations and Pharmacokinetic Profiling
Sameh S. Elhady, Noha M. Alshobaki, Mahmoud A. Elfaky, Abdulrahman E. Koshak, Majed Alharbi, Reda F. A. Abdelhameed, Khaled M. Darwish
Metabolites.2023; 13(8): 942. CrossRef
Change of metformin concentrations in the liver as a pharmacological target site of metformin after long-term combined treatment with ginseng berry extract
Choong Whan Lee, Byoung Hoon You, Sreymom Yim, Seung Yon Han, Hee-Sung Chae, Mingoo Bae, Seo-Yeon Kim, Jeong-Eun Yu, Jieun Jung, Piseth Nhoek, Hojun Kim, Han Seok Choi, Young-Won Chin, Hyun Woo Kim, Young Hee Choi
Frontiers in Pharmacology.2023;[Epub] CrossRef
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
Life.2023; 13(4): 1012. CrossRef
The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials
Mohammad Zamani, Mahlagha Nikbaf-Shandiz, Yasaman Aali, Niloufar Rasaei, Mahtab Zarei, Farideh Shiraseb, Omid Asbaghi
Frontiers in Nutrition.2023;[Epub] CrossRef
The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials
Mohsen Yousefi, Sahand Tehrani Fateh, Mahlagha Nikbaf-Shandiz, Fatemeh Gholami, Samira Rastgoo, Reza Bagher, Alireza Khadem, Farideh Shiraseb, Omid Asbaghi
BMC Pharmacology and Toxicology.2023;[Epub] CrossRef
A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults
Sina Raissi Dehkordi, Naseh Pahlavani, Mahlagha Nikbaf-Shandiz, Reza Bagheri, Niloufar Rasaei, Melika Darzi, Samira Rastgoo, Hossein Bahari, Farideh Shiraseb, Omid Asbaghi
Journal of Diabetes & Metabolic Disorders.2023; 23(1): 135. CrossRef
Inhibitory activity of xanthoangelol isolated from Ashitaba (Angelica keiskei Koidzumi) towards α-glucosidase and dipeptidyl peptidase-IV: in silico and in vitro studies
Diah Lia Aulifa, I Ketut Adnyana, Sukrasno Sukrasno, Jutti Levita
Heliyon.2022; 8(5): e09501. CrossRef
Design, synthesis, and in silico studies of benzimidazole bearing phenoxyacetamide derivatives as α-glucosidase and α-amylase inhibitors
Nahal Shayegan, Aida Iraji, Nasim Bakhshi, Ali Moazzam, Mohammad Ali Faramarzi, Somayeh Mojtabavi, Seyyed Mehrdad Mostafavi Pour, Maliheh Barazandeh Tehrani, Bagher Larijani, Zahra Rezaei, Pardis Yousefi, Mehdi Khoshneviszadeh, Mohammad Mahdavi
Journal of Molecular Structure.2022; 1268: 133650. CrossRef
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, S. Sethu Reddy, Janet B. McGill, Sarah L. Berga, Michael Bush, Suchitra Chandrasekaran, Ralph A. DeFronzo, Daniel Einhorn, Rodolfo J. Galindo, Thomas W. Gardner, Rajesh Garg, W. Timothy Garvey, Irl B. Hirsch, Danie
Endocrine Practice.2022; 28(10): 923. CrossRef
Combination of Bawang Dayak Extract and Acarbose against Male White Rat Glucose Levels
Aditya Maulana Perdana Putra, Ratih Pratiwi Sari, Siska Musiam
Borneo Journal of Pharmacy.2021; 4(2): 84. CrossRef
Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs
Massimo Genovese, Ilaria Nesi, Anna Caselli, Paolo Paoli
Molecules.2021; 26(16): 4818. CrossRef
Impact of Simulated Gastrointestinal Conditions on Antiglycoxidant and α-Glucosidase Inhibition Capacities of Cyanidin-3-O-Glucoside
Didier Fraisse, Alexis Bred, Catherine Felgines, François Senejoux
Antioxidants.2021; 10(11): 1670. CrossRef

Current Status of Prescription in Type 2 Diabetic Patients from General Hospitals in Busan: Ji Hye Suk, Chang Won Lee, Sung Pyo Son, Min Cheol Kim, Jun Hyeob Ahn, Kwang Jae Lee, Ja Young Park, Sun Hye Shin, Min Jeong Kwon, Sang Soo Kim, Bo Hyun Kim, Soon Hee Lee, Jeong Hyun Park, In Joo Kim; Diabetes Metab J. 2014;38(3):230-239. Published online June 17, 2014; DOI: https://doi.org/10.4093/dmj.2014.38.3.230

7,330 View
38 Download
9 Web of Science
9 Crossref

Abstract PDF PubReader

Background

Data regarding the prescription status of individuals with diabetes are limited. This study was an analysis of participants from the relationship between cardiovascular disease and brachial-ankle pulse wave velocity in patients with type 2 diabetes (REBOUND) Study, which was a prospective multicenter cohort study recruited from eight general hospitals in Busan, Korea. We performed this study to investigate the current status of prescription in Korean type 2 diabetic patients.

Methods

Type 2 diabetic patients aged 30 years or more were recruited and data were collected for demographics, medical history, medications, blood pressure, and laboratory tests.

Results

Three thousands and fifty-eight type 2 diabetic patients were recruited. Mean age, duration of diabetes, and HbA1c were 59 years, 7.6 years, and 7.2%, respectively. Prevalence of hypertension was 66%. Overall, 7.3% of patients were treated with diet and exercise only, 68.2% with oral hypoglycemic agents (OHAs) only, 5.3% with insulin only, and 19.2% with both insulin and OHA. The percentage of patients using antihypertensive, antidyslipidemic, antiplatelet agents was similar as about 60%. The prevalence of statins and aspirin users was 52% and 32%, respectively.

Conclusion

In our study, two thirds of type 2 diabetic patients were treated with OHA only, and one fifth with insulin plus OHA, and 5% with insulin only. More than half of the patients were using each of antihypertensive, antidyslipidemic, or antiplatelet agents. About a half of the patients were treated with statins and one third were treated with aspirin.

Citations

Citations to this article as recorded by

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef
Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study
Jeong Mi Kim, Sang Soo Kim, In Joo Kim, Jong Ho Kim, Bo Hyun Kim, Mi Kyung Kim, Soon Hee Lee, Chang Won Lee, Min Chul Kim, Jun Hyeob Ahn, Jinmi Kim
Cardiovascular Diabetology.2020;[Epub] CrossRef
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim
Diabetes & Metabolism Journal.2020; 44(1): 67. CrossRef
Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee
Journal of Diabetes.2017; 9(4): 412. CrossRef
Arterial Stiffness Is More Associated with Albuminuria than Decreased Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus: The REBOUND Study
Jong Ho Kim, Sang Soo Kim, In Joo Kim, Bo Hyun Kim, Ja Young Park, Chang Won Lee, Ji Hye Suk, Sun Hae Shin, Sung Pyo Son, Min Chul Kim, Jun Hyeob Ahn, Kwang Jae Lee, Min Jung Kwon, Soon Hee Lee, Jeong Hyun Park
Journal of Diabetes Research.2017; 2017: 1. CrossRef
Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
The Korean Journal of Internal Medicine.2017; 32(6): 967. CrossRef
Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
Diabetes & Metabolism Journal.2017; 41(5): 367. CrossRef
Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
Yeoree Yang, Jeong-Ah Shin, Hae Kyung Yang, Seung-Hwan Lee, Seung-Hyun Ko, Yu-Bae Ahn, Kun-Ho Yoon, Jae-Hyoung Cho
Diabetes & Metabolism Journal.2016; 40(6): 454. CrossRef
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim
Diabetes & Metabolism Journal.2016; 40(3): 230. CrossRef

First
Prev
Page of 1
Next
Last

Search